A drug cost analysis expert reveals that the life-saving drug Risdiplam, used to treat the rare genetic disease SMA, could ...

Researchers have uncovered a mechanism that may trigger ALS’s earliest stages, identifying proteins that mislocalize, causing ...

"We're intrigued because there are actually therapeutics for spinal muscular atrophy," Yeo said. "One of them, risdiplam, is ...

A Yale expert reveals SMA drug Risdiplam could cost Rs 3,000 annually with local production, vastly cheaper than Rs 72 lakh ...

Risdiplam is a potential rival to Biogen’s Spinraza (nusinersen), a spinally injected antisense drug that tells the body to produce the SMN protein that is defective in patients with SMA and has ...

A drug pricing expert reveals the shocking cost disparity of a life-saving spinal muscular atrophy drug in India, priced at ...

While Roche’s oral risdiplam has been tipped by some analysts to be a big contender in the market for spinal muscular atrophy (SMA) treatments, Novartis’ research chief Jay Bradner has a ...

Patient advocates push for generic drug production to treat rare diseases, facing patent barriers and high costs.

Roche, a Swiss multinational healthcare company, is seeking a permanent injunction against Natco Pharma to prevent the introduction of a generic version of Risdiplam, a Spinal Muscular Atrophy (SMA) ...

Health groups and patients calls for government interference to make rare disease drugs affordable: Our Bureau, New Delhi Tuesday, November 5, 2024, 18:10 Hrs [IST] Health groups ...

Roche’s action in Delhi High Court seeking an injunction against Natco Pharma to prevent the introduction of a generic ...

Patients with rare diseases in India, like Saifullah Khalidi with spinal muscular atrophy (SMA), struggle to afford ...